692 related articles for article (PubMed ID: 28080053)
21. Efficient co-delivery of immiscible hydrophilic/hydrophobic chemotherapeutics by lipid emulsions for improved treatment of cancer.
Zhang B; Song Y; Wang T; Yang S; Zhang J; Liu Y; Zhang N; Garg S
Int J Nanomedicine; 2017; 12():2871-2886. PubMed ID: 28435264
[TBL] [Abstract][Full Text] [Related]
22. Structural and chemical aspects of HPMA copolymers as drug carriers.
Ulbrich K; Subr V
Adv Drug Deliv Rev; 2010 Feb; 62(2):150-66. PubMed ID: 19931329
[TBL] [Abstract][Full Text] [Related]
23. Nanoprecipitation and the "Ouzo effect": Application to drug delivery devices.
Lepeltier E; Bourgaux C; Couvreur P
Adv Drug Deliv Rev; 2014 May; 71():86-97. PubMed ID: 24384372
[TBL] [Abstract][Full Text] [Related]
24. Sugar-based amphiphilic polymers for biomedical applications: from nanocarriers to therapeutics.
Gu L; Faig A; Abdelhamid D; Uhrich K
Acc Chem Res; 2014 Oct; 47(10):2867-77. PubMed ID: 25141069
[TBL] [Abstract][Full Text] [Related]
25. Drug Delivery Vehicles Based on Albumin-Polymer Conjugates.
Jiang Y; Stenzel M
Macromol Biosci; 2016 Jun; 16(6):791-802. PubMed ID: 26947019
[TBL] [Abstract][Full Text] [Related]
26. Lipid nanocarriers: influence of lipids on product development and pharmacokinetics.
Pathak K; Keshri L; Shah M
Crit Rev Ther Drug Carrier Syst; 2011; 28(4):357-93. PubMed ID: 21967401
[TBL] [Abstract][Full Text] [Related]
27. Advances in the use of prodrugs for drug delivery to the eye.
Taskar P; Tatke A; Majumdar S
Expert Opin Drug Deliv; 2017 Jan; 14(1):49-63. PubMed ID: 27441817
[TBL] [Abstract][Full Text] [Related]
28. [Advances in polymer-drug conjugated micelles in the delivery of anticancer drugs].
Yin XL; Zhang B; Liu YJ; Zhang N
Yao Xue Xue Bao; 2016 May; 51(5):710-6. PubMed ID: 29874007
[TBL] [Abstract][Full Text] [Related]
29. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part II - Ocular drug-loaded lipid nanoparticles.
Sánchez-López E; Espina M; Doktorovova S; Souto EB; García ML
Eur J Pharm Biopharm; 2017 Jan; 110():58-69. PubMed ID: 27789359
[TBL] [Abstract][Full Text] [Related]
30. Design of Zein Conjugation and Surface Modification for Targeting Drug Delivery.
Tran PH; Tran TT
Curr Drug Targets; 2020; 21(4):406-415. PubMed ID: 31518220
[TBL] [Abstract][Full Text] [Related]
31. Solid Lipid-Polymer Hybrid Nanoparticles by In Situ Conjugation for Oral Delivery of Astaxanthin.
Wang T; Hu Q; Lee JY; Luo Y
J Agric Food Chem; 2018 Sep; 66(36):9473-9480. PubMed ID: 30130387
[TBL] [Abstract][Full Text] [Related]
32. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
Qu J; Zhang L; Chen Z; Mao G; Gao Z; Lai X; Zhu X; Zhu J
Drug Deliv; 2016 Nov; 23(9):3408-3416. PubMed ID: 27181462
[TBL] [Abstract][Full Text] [Related]
33. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy.
Luo C; Sun J; Sun B; He Z
Trends Pharmacol Sci; 2014 Nov; 35(11):556-66. PubMed ID: 25441774
[TBL] [Abstract][Full Text] [Related]
34. In vivo fate of lipid-silybin conjugate nanoparticles: Implications on enhanced oral bioavailability.
Ma Y; He H; Xia F; Li Y; Lu Y; Chen D; Qi J; Lu Y; Zhang W; Wu W
Nanomedicine; 2017 Nov; 13(8):2643-2654. PubMed ID: 28778838
[TBL] [Abstract][Full Text] [Related]
35. Perspectives on cutting-edge nanoparticulate drug delivery technologies based on lipids and their applications.
Maddiboyina B; Ramaiah ; Nakkala RK; Roy H
Chem Biol Drug Des; 2023 Aug; 102(2):377-394. PubMed ID: 36916008
[TBL] [Abstract][Full Text] [Related]
36. Polymeric Biomaterial and Lipid Based Nanoparticles for Oral Drug Delivery.
Dilnawaz F
Curr Med Chem; 2017; 24(22):2423-2438. PubMed ID: 27804879
[TBL] [Abstract][Full Text] [Related]
37. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
38. Recent Trends in Clinical Trials Related to Carrier-Based Drugs.
Tagami T; Ozeki T
J Pharm Sci; 2017 Sep; 106(9):2219-2226. PubMed ID: 28259767
[TBL] [Abstract][Full Text] [Related]
39. Lipids and their derivatives: by-products used as essential building blocks for modern drug delivery systems.
Tu Y; Zhu L
Curr Drug Targets; 2014 May; 15(5):502-17. PubMed ID: 24597533
[TBL] [Abstract][Full Text] [Related]
40. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration.
Gaba B; Fazil M; Ali A; Baboota S; Sahni JK; Ali J
Drug Deliv; 2015; 22(6):691-700. PubMed ID: 24670099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
